A Descriptive Review of Nordic Clinical Practice Guidelines for Pediatric ADHD: Evaluating the Evidence Base for
1Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.
Background:
Pediatric medication use in Attention Deficit Hyperactivity Disorder (ADHD) is rising sharply across the Nordic countries, with Iceland and Finland currently showing the highest prevalence rates. The reasons behind the cross -country differences remain unclear.
Objective:
To describe the level of agreement in the graded evidence base for methylphenidate - the first-line ADHD medication for children - as is available in the Nordic Clinical Practice Guidelines (CPGs) on pediatric ADHD.
Method:
Relevant Nordic CPGs covering ADHD medication treatment for children over 6 years-of-age were identified using strict search criteria and by visiting the Nordic CPG databases (in Nov 2025). Only the most current version of CPGs was included in the analysis and relevant links from the CPG were visited and reviewed with relevant sections adopted. All english translations were produced with the aid of large linguistic models.
Results:
The Icelandic CPG lacked the grading of available evidence for methylphenidate altogether. For benefits, the chosen outcomes varied and the Finnish and Norwegian CPGs graded the quality of evidence as of high quality, the Danish as moderate and the Swedish from moderate to very low. For potential harms associated with methylphenidate use, also the Norwegian CPGs lacked the grading of evidence. The Finnish CPG concluded on high to moderate quality of evidence, the Swedish on moderate to very low and the Danish only on very low quality of evidence.
Conclusions:
There is a low level of agreement between Nordic guidelines regarding the quality of evidence for methylphenidate in pediatric ADHD. This could contribute to the observed cross-country differences in prescribing practices. A centralized CPG development process and stronger collaboration among Nordic CPG working groups seem warranted.
More Related Videos
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
01:28Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:25Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:30Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...